MINIVELLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINIVELLE (MINIVELLE).
Estradiol binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and regulation of target tissues including reproductive, cardiovascular, skeletal, and CNS systems.
| Metabolism | Primarily hepatic metabolism via CYP3A4 to estrone and estriol, followed by conjugation (glucuronidation, sulfation). |
| Excretion | Renal: 80-90% as glucuronide and sulfate conjugates; Fecal: 10-20% via bile; <1% unchanged. |
| Half-life | Terminal half-life: 12-18 hours for estradiol; clinical context: once-daily or twice-weekly dosing maintains steady-state concentrations. |
| Protein binding | 98% bound primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Approximately 1.2-1.5 L/kg; extensive distribution into tissues. |
| Bioavailability | Transdermal: approximately 82% of dose absorbed (avoid first-pass metabolism); oral: <5% due to extensive hepatic first-pass. |
| Onset of Action | Transdermal: detectable plasma levels within 1-2 hours; clinical effect (e.g., symptom relief) within 1-2 weeks. |
| Duration of Action | Transdermal: sustained release over 3-7 days depending on patch wear time; clinical effect persists as long as patch is applied. |
Transdermal: Apply 0.025-0.1 mg/day patch twice weekly (every 3-4 days).
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No specific dosage adjustment recommended; use with caution in severe impairment. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use lowest effective dose. |
| Pediatric use | Safety and efficacy not established; not FDA-approved for pediatric use. |
| Geriatric use | Use lowest effective dose; monitor for thromboembolic events and malignancy; consider shorter duration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MINIVELLE (MINIVELLE).
| Breastfeeding | Estradiol is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. Infant exposure is considered low, but estrogens may reduce milk production and composition. Use during breastfeeding is generally not recommended, especially in the early postpartum period. Consider alternatives. |
| Teratogenic Risk | Estrogens, including estradiol (MINIVELLE), are contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, particularly cardiovascular and urogenital defects. Second and third trimester exposure may increase risk of fetal reproductive tract abnormalities, including vaginal adenosis and clear cell adenocarcinoma in female offspring. Estrogens should not be used during pregnancy. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Use progestin when uterus is present. Do not use for prevention of cardiovascular disease or dementia. Increased risk of probable dementia in women ≥65 years. Increased risk of breast cancer, stroke, DVT, and pulmonary embolism.
| Serious Effects |
Undiagnosed abnormal genital bleeding, known/suspected breast cancer (except certain metastatic cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history thereof, active arterial thromboembolic disease (e.g., stroke, MI), known protein C/protein S/antithrombin deficiency, liver impairment or disease, known pregnancy, hypersensitivity to estradiol or components.
| Precautions | Cardiovascular disorders (stroke, MI, DVT), malignant neoplasms (endometrial, breast, ovarian), dementia, gallbladder disease, hypercalcemia, visual abnormalities, hereditary angioedema, exacerbation of endometriosis, and fluid retention. Minimize dose and duration. |
Loading safety data…
| Fetal Monitoring | Monitor blood pressure, uterine growth, and fetal heart rate if inadvertently used during pregnancy. In cases of accidental exposure, assess for signs of fetal distress. Monitor for maternal adverse effects such as thromboembolism and hypertension. |
| Fertility Effects | Estrogens suppress gonadotropin secretion, potentially inhibiting ovulation and reducing fertility. Reversible upon discontinuation. Use as contraception is not indicated due to thrombotic risks. |